Table 1.
A summary of monoclonal antibodies used in cancer medicine or in development
| Cancer | Target antigen | Monoclonal antibody (Ref) | Clinical status |
|---|---|---|---|
| Non-Hodgkin lymphoma | CD20 | Rituximab (7–20) | In clinical use |
| 90Y-ibritumomab tiuxetan | In clinical use | ||
| 131I-tositumomab | In clinical use | ||
| CD22 | Epratuzumab (56) | In clinical trials | |
| 90Y-epratuzumab | In clinical trials | ||
| HLA-DR | Remitogen (57) | In clinical trials | |
| Acute myeloid leukaemia | CD33 | Gemtuzumab ozogamicin (52–55) | In clinical use |
| B-cell chronic lymphocytic leukaemia | CD52 | Alemtuzumab (58) | In clinical use |
| Colorectal cancer | Epidermal growth factor receptor (also in trials in head and neck and non-small-cell lung carcinoma) | Cetuximab (26–35) | In clinical use |
| h-R3 (59) | In clinical trials | ||
| ABX-EGF (60) | In clinical trials | ||
| A33 | huA33 (61) | In clinical trials | |
| Renal cell carcinoma | G250 | cG250 (62) | In clinical trials |
| Melanoma | GD3 | KW-2189 (63) | In clinical trials |
| Breast cancer | HER2 (C-erb2) | Trastuzumab (36–45) | In clinical use |
| Prostate cancer | Prostate-specific membrane antigen | HuJ591 (64) | In clinical trials |
| Small-cell lung cancer | CD56 | BB-10901 (65) | In clinical trials |
| Solid tumours | Vascular endothelial growth factor (VEGF) | Bevacizumab (47–51) | In clinical use for metastatic colorectal cancer and in clinical trials in other tumour types |
| VEGF2 | IMC-1C11 (66) | In clinical trials | |
| Epithelial cancers | Carcinoembryonic antigen | 90Y-CEA-cide (67) | In clinical trials |
| Lewis Y antigen | Hu3S193 (68) | In clinical trials |